Strong share price support for early movers in medical cannabis industry.
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
A raft of new Federal legislation that initially legalised the use of medical cannabis and just this week approved the importation of the product to fill a supply gap will benefit a number of ASX listed companies that have been active in growing and distributing the product in overseas regions.
Only a limited amount of medical cannabis is currently being produced in Australia, and with the new legislation coming into effect immediately it is anticipated that demand will substantially outstrip supply.
Investors have already picked up on the story with some stocks surging in anticipation of positive news and others just recently rerating sharply, particularly those that are equipped to immediately export into the Australian market.
It should be noted that share trading patterns should not be used as the basis for an investment and past performance may or may not be replicated. Those considering the three stocks mentioned in this article should seek independent financial advice.
One such company that was targeted yesterday was MGC Pharmaceuticals (ASX: MXC). Its shares increased by nearly 16%, and yesterday’s closing price of 5.1 cents represented a gain of 35% over the last week.
However, there have been other positive factors driving the stock’s share price and these are outlined in yesterday’s FinFeed article, MGC Pharmaceuticals positioned to snare early share of the Australian medical cannabis market.
Creso Pharma
Another player in that space is Creso Pharma (ASX: CPH). Its share price hit an intraday high of 28.5 cents on Thursday, representing a gain of 20% over the last week.
The company announced on February 14 that it had achieved solid progress with the first fully plant-based cannabidiol nutraceutical product which assists in the management of anxiety and stress.
From a broader perspective, the anxiety and stress management industry is an important one for CPH as 2015 data indicates the market was valued at US$3.5 billion.
CPH develops cannabis and hemp derived therapeutic grade cannabidiol nutraceuticals and medical cannabis products with wide patient reach for human and animal health.
The group has registrations in Switzerland for its products and worldwide rights for a number of unique and proprietary delivery technologies which enhance the bioavailability and absorption of cannabinoids. CPH is already generating revenues via its subsidiary, Hemp-Industries.
With regard to recent regulatory changes in Australia, CPH is well-positioned following the signing of its first Australian Letter of Intent (LOI) with Western Australian based pharmaceutical group Health House International.
This occurred at the start of February, and will facilitate the import and sale of cannabis products in the Australian market.
The other interesting aspect of CPH’s business is its progress in the animal health market. In mid-January, CPH announced that it and Greveling Holding BV were the first companies globally to be awarded European Union registration for two cannabidiol-based (CBD) proprietary formulation animal feed nutraceutical products.
The first mover advantage will help CPH capture a leading share of the global companion animal market with its CBD nutraceuticals and a leading market share of the hemp derived animal health market worldwide.
CPH is targeting Switzerland, Europe, the Middle East, the Gulf region and Latin America with its commercialisation partners. It is estimated that this market will be worth US$39.7 billion by 2021.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
